Abstract
The aim of this study was to develop a stable parenteral dosage form for the investigational cytotoxic drug [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11} (Substance P Antagonist G; Antagonist G). Antagonist G bulk drug was structurally and analytically characterized. The drug exhibits excellent aqueous solubility, although relatively poor aqueous stability characteristics. Lyophilization was, therefore, selected as the manufacturing process. Differential scanning calorimetry studies were conducted to determine the freeze-drying cycle parameters which resulted in a stable, lyophilized formulation of Antagonist G. The prototype, containing 50 mg Antagonist G per vial, was found to be the optimal formulation in terms of solubility, length of the freeze-drying cycle, stability, and dosage requirements in the planned phase I clinical trials. Quality control of the freeze-dried formulation showed that the manufacturing process does not change the integrity of Antagonist G. Shelf life studies demonstrated that the formulation is stable for at least 3 years, when stored at 2–8°C in a dark environment. Oxidative degradation products of Antagonist G were isolated and structurally characterized by mass spectrometry, nuclear magnetic resonance spectroscopy, and infrared spectroscopy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Woll PJ, Rozengurt E: [D-Arg1, D-Phe5, D-Trp7;9, Leu11]-Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA 85: 1859–1863, 1988
Woll PJ, Rozengurt E: A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 50: 3968–3973, 1990
Everard MJ, Macaulay VM, Millar JL, Smith IE: [D-Arg1, D-Phe5, D-Trp7;9, Leu11]-Substance P inhibits the growth of human small cell lung cancer xenografts in vivo. Eur J Cancer 29A: 1450–1453, 1993
Sethi T, Langdon S, Smyth J, Rozengurt E: Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitroand in vivo. Cancer Res 52: 2737s-2742s, 1992
Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E: Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52: 4554–4557, 1992
Manning MC, Patel K, Borchardt RT: Stability of protein pharmaceuticals. Pharm Res 6: 903–918, 1989
Oliyai C, Schoneich C, Wilson GS, Borchardt RT: In Topics in pharmaceutical sciences 1991, (eds) D.J.A. Crommelin and K.K. Mihda, Medpharm Scientific Publishers, Stuttgart, pp. 23–46, 1992
Brot N, Weissbach H: Biochemistry and physiological role of methionine sulfoxide residues in proteins. Arch Biochem Biophys 223: 271–281, 1983
Whitaker JR, Feeney RE: Chemical and physical modification of proteins by the hydroxide ion. CRC Crit Rev Food Sci Nutr 19: 173–212, 1983
Cummings J, MacLellan A, Langdon SP, Smyth JF: Stability and in vitrometabolism of the mitogenic neuropeptide antagonists [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P and [Arg6, D-Trp7,9, MePhe8]-Substance P 6–11 characterized by high-performance liquid chromatography. J Pharm Biomed Anal 12: 811–819, 1994
Reubsaet JLE, Beijnen JH, Bult A, Teeuwsen J, Koster EHM, Waterval JCM, Underberg WJM: Reversed-phase high-performance liquid chromatography and capillary electrophoresis in the stability study of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6–11}: a comparative study. Anal Biochem 220: 98–102, 1994
Reubsaet JLE, Beijnen JH, Bult A, Van Der Houwen OAGJ, Teeuwsen J, Koster EHM, Waterval JCM, Underberg WJM: Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6–11} in aqueous solution. Anal Biochem 227:334–341, 1995
Davignon JP, Slack JA, Beijnen JH, Vezin WR, Schoemaker TJ: EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs. Eur J Cancer Clin Oncol 24: 1535–1538, 1988
Martin AN, Swarbrick J, Cammarata A: In Physical Pharmacy, Lea & Febiger, Philadelphia, pp. 189– 235, 1969
Roepstorff P, Fohlman J: Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed Mass Spectrom 11: 601, 1984
Reubsaet JLE, Beijnen JH, Bult A, Hop E, Vermaas R, Kellekule Y, Kettenes-van den Bosch JJ, Underberg WJM: Structural identification of the degradation products of the antitumor peptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance 6 {6–11}. Anal Chem 67: 4431–4436, 1995
Pecsok RL, Shields LD, Cairns T, McWilliam IG: In Modern Methods of Chemical Analysis, 2nd edition, John Wiley & Sons, New York, USA, pp. 174–175, 1976
Hsu CC, Ward CA, Pearlman R, Nguyen HM, Yeung DA, Curley JG: Determination of optimum residual moisture in lyophilized protein pharmaceuticals. Develop Biol Standard 74: 255–271, 1991
Vemuri S, Yu CD, Roosdorp N: Effect of cryoprotectants on freezing, lyophilization and storage of lyophilized recombinant alpha-antitrypsin formulations. PDA J Pharm Sci Technol 48: 241–246, 1994
Baffi RA, Garnick RL: Quality control issues in the analysis of lyophilized proteins. Develop Biol Standard 74: 181–184, 1991
Anonymous: Draft guideline for validation of the limulus amoebocyte lysate test as an end product endotoxin test for human and animal parenteral drugs and medical devices. Washington DC: Food and Drug Administration: 33–34, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jonkman-de Vries, J., Rosing, H., Talsma, H. et al. Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11}. Invest New Drugs 16, 99–111 (1998). https://doi.org/10.1023/A:1006041024109
Issue Date:
DOI: https://doi.org/10.1023/A:1006041024109